In the mid-1990s, Japan was not merely participating in the global pharmaceutical industry—it was shaping it. […]
Just now, AstraZeneca is making headlines with a $5.3 billion AI research partnership with China’s […]
Japan’s IVD sector remains highly structured and closely governed, benefiting from a mature healthcare infrastructure and […]
Some of Japan’s most forward-thinking minds gathered to scrutinise Japan’s biobank conundrum at Shonan iPark. In […]
Navigating Japan’s life sciences sector successfully hinges on more than just excellent science or a meticulously […]
It started with a headline I read on the train to kendo practice. AstraZeneca is setting […]
Is Japan’s Drug Pricing Squeeze Finally Loosening? Japan has long been a high-pressure pricing environment for […]
Japan has set ambitious goals to advance its bioeconomy, aiming to integrate biotechnology across various sectors […]
Japan represents one of the world’s most demanding pharmaceutical markets, with rigorous quality standards that go […]
Advanced Therapy Medicinal Products (ATMPs) represent a rapidly evolving field in biotechnology, offering transformative therapeutic solutions […]